What is IBRX's current stock price?

As of now, IBRX is trading at $6.33, with a daily change of +3.26%.

What are the risks associated with IBRX stock?

IBRX has Low, risk level based on volatility, sector strength, volume, investor confidence and outlook.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

IBRX Stock Analysis & IQ Rating | ImmunityBio

IBRX

ImmunityBio

$6.33

+$0.20 | +3.26%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$8.28

MKT CAP

$6.23B

52W Low

$1.83

VOL

$20.92M

P/E Ratio

N/A

AVG VOL

$39.89M

RSI

70.40

TREND

Uptrend

IBRX Stock IQ

Login to see ImmunityBio (IBRX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

IBRX Target Price

Login to display

Strengths

IBRX Rewards

Upgraded on attractively valued

IBRX Rewards

Earnings are forecast to grow

IBRX Rewards

Investors confidence is positive

Technical Indicators

IBRX Technical Indicators

Overbought

IBRX Price Performance

$2.08 (+204.33%)

$2.15 (+194.42%)

$2.57 (+146.30%)

$3.35 (+88.96%)

1year

6month

3month

1month

IBRX Analysts Opinion

Overall standing based on market and analyst consensus. menu Hover over the category for more information

IBRX Analysts Opinion

IBRX Analysts opinion is positive and also has improved from the past 3 months

IBRX Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

93%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

86%

80%

IBRX Street Sentiment

IBRX Street Sentiment is extremely bullish and have positive views on the near-term outlook

IBRX Risk Level

IBRX has Low risk level

Risks Indicators

Price under $5

High volatilty

Low

LOW

HIGH

IBRX Performance Sentiment

Sentiments overview associated with events and the stock performance

93%

7%

Positive

Negative

57 out of 61
events present

4 out of 61
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support
Price

$6.25

Resistance
Price

$2.02

Current Price Range

$7.34

Show methods +

Analyst Consensus

Recent Upgrades and Downgrades

100%

Buy

Hold

Sell

Consensus Rating

STRONG BUY

3

0

Date

Action

Rating

Firm

Dec 17, 2025

Reiterate

Buy

D. Boral Capital

Dec 13, 2025

Reiterate

Buy

Jefferies

Dec 12, 2025

Reiterate

Buy

D. Boral Capital

Nov 14, 2025

Reiterate

Buy

D. Boral Capital

Nov 06, 2025

Reiterate

Buy

D. Boral Capital

Linked to IBRX

Close Price

Change

CRSP

CRISPR Therapeutics

52.00

+1.34%

CLDI

Calidi Biotherapeutics In

0.99

-1.00%

Recently Viewed

Close Price

Change

IBRX

ImmunityBio

6.33

+3.26%

ADT

ADT Inc.

7.77

-2.88%

XRX

Xerox

2.17

-5.65%

FNKO

Funko Inc.

4.11

-0.96%

CRM

Salesforce

196.38

-6.85%

IBRX Latest Analysis +

Piper Sandler See Label Expansion Potential for ImmunityBio Inc. (IBRX)s ANKTIVA Following QUILT Data. We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. ImmunityBio Inc. is among the best biotech stocks. TheFly reported on January 20 that Piper Sandler raised its price target on IBRX to $7 from $5 and maintained an Overweight rating. According to the update United States ANKTIVA net sales increased by almost 700% year [….]

Mon Feb 2, 2026

$6.13 | -1.92%

Activity

Potential

How Is The Market Feeling About ImmunityBio Inc?. ) short interest as a percent of float has risen 10.65% since its last report. According to exchange reported data there are now Short interest is the number of shares that have been sold short but have not yet been covered or closed out. is when a trader sells shares of a company they do not own with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.Short ...

Wed Jan 28, 2026

$6.15 | +3.36%

Momentum

Stock Market Today Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer. ImmunityBio (NASDAQ:IBRX) an immunotherapy and infectious disease drug maker closed Tuesday at $6.48 up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label expansion in bladder cancer and investors are watching next steps on the planned

Mon Jan 26, 2026

$6.21 | -3.72%

Activity

Momentum

Stock Market Today Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month. ImmunityBio (NASDAQ:IBRX) an immunity-focused biotech closed Friday&rsquo.s session at $6.45 down 12.13%. The stock is still up 63.29% in the past five days and 207.14% in the past month.

Fri Jan 23, 2026

$6.45 | -12.13%

Momentum

Stock Market Today Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses. ImmunityBio (NASDAQ:IBRX) which develops immunotherapies for cancers and infectious diseases closed Wednesday at $6.92 up 6.79%. The stock moved higher as short-sellers considered what to do after the company&rsquo.s share price tripled in just three weeks this year. Trading volume

Wed Jan 21, 2026

$6.92 | +6.79%

Momentum

ImmunityBio rally causes $492M paper losses for short sellers.

Wed Jan 21, 2026

$6.92 | +6.79%

Momentum

ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission. IBRX stock jumps 17% after FDA talks outline the path to resubmit Anktiva sBLA for papillary NMIBC with additional analyses done and filing planned soon.

Wed Jan 21, 2026

$6.92 | +6.79%

Momentum

ImmunityBio (IBRX) Rockets on 12th Day Hits Fresh High. We recently published 10 Stocks Breaking Records While Wall Street Bleeds. ImmunityBio Inc. (NASDAQ:IBRX) was one of the top performers on Tuesday. ImmunityBio saw its share prices rally for a 12th consecutive day on Tuesday reaching a fresh 52-week high as investors took heart from developments in its supplemental biologics license application (BLA) for Anktiva [….]

Wed Jan 21, 2026

$6.92 | +6.79%

Momentum

Potential

Stock Market Today Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer. ImmunityBio (NASDAQ:IBRX) an immunotherapy and infectious disease drug maker closed Tuesday at $6.48 up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label expansion in bladder cancer and investors are watching next steps on the planned

Tue Jan 20, 2026

$6.48 | +17.39%

Activity

Momentum

ImmunityBio Advances FDA Path For ANKTIVA In BCG-Unresponsive Papillary Bladder Cancer. Stock Soars . (RTTNews) - ImmunityBio Inc. (IBRX) announced that it has made progress in regulatory discussions with the FDA regarding a potential resubmission of its supplemental Biologics License Application (sBLA) for ANKTIVA (nogapendekin alfa inbakicept) in patients with BCG-unresponsive

Tue Jan 20, 2026

$6.48 | +17.39%

Momentum

FAQ About IBRX Stock Insights

What is IBRX current stock price?

What are IBRX stock strengths?

What is IBRX Risk Level?

What is IBRX market cap and volume?

What is IBRX current Stock IQ?

Should I buy IBRX stock right now?

Is IBRX a Strong Buy right now?

What does a 'Strong Buy' rating mean for IBRX?

What does a 'Strong Sell' rating mean for IBRX?

What factors influence IBRX's Stock IQ?

Explore our IBRX Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored IBRX Stock Strategies
Effective Risk Management

FIND US ON

Receive our IBRX Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

IBRX

ImmunityBio

Set Alerts

Current Price

$6.33

+$0.20 | +3.26%

52W High

$8.28

MKT CAP

$6.23B

52W Low

$1.83

VOL

$20.92M

P/E Ratio

N/A

AVG VOL

$39.89M

RSI

70.40

TREND

Uptrend

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Linked to IBRX

Symbol

Close

Change

CRSP

CRISPR Therapeutics

52.00

+1.34%

CLDI

Calidi Biotherapeutics In

0.99

-1.00%

IBRX Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

93%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

86%

80%

IBRX Street Sentiment

IBRX Street Sentiment is extremely bullish and have positive views on the near-term outlook

IBRX Risk Level

IBRX has Low risk level

Risks Indicators

Price under $5

High volatilty

Low

LOW

HIGH

IBRX Performance Sentiment

Sentiments overview associated with events and the stock performance.

93%

7%

Positive

Negative

57 out of 61
events present

4 out of 61
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support
Price

$6.25

Resistance
Price

$2.02

Current Price Range

$7.34

Show methods +

Latest Analyst Actions

Overall Wall Street Rating

100%

Buy

Hold

Sell

Consensus Rating

STRONG BUY

3

0

Date

Action

Rating

Firm

Dec 17, 2025

Reiterate

Buy

D. Boral Capital

Dec 13, 2025

Reiterate

Buy

Jefferies

Dec 12, 2025

Reiterate

Buy

D. Boral Capital

Nov 14, 2025

Reiterate

Buy

D. Boral Capital

Nov 06, 2025

Reiterate

Buy

D. Boral Capital

IBRX Stock IQ

Login to unlock ImmunityBio (IBRX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Target Price

Login to display

Stock Insights

Strengths

IBRX Rewards

Upgraded on attractively valued

IBRX Rewards

Earnings are forecast to grow

IBRX Rewards

Investors confidence is positive

Technical Indicators

IBRX Technical Indicators

Overbought

IBRX Latest Analysis

Piper Sandler See Label Expansion Potential for ImmunityBio Inc. (IBRX)s ANKTIVA Following QUILT Data. We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. ImmunityBio Inc. is among the best biotech stocks. TheFly reported on January 20 that Piper Sandler raised its price target on IBRX to $7 from $5 and maintained an Overweight rating. According to the update United States ANKTIVA net sales increased by almost 700% year [….]

Mon Feb 2, 2026

$6.13 | -1.92%

Activity

Potential

How Is The Market Feeling About ImmunityBio Inc?. ) short interest as a percent of float has risen 10.65% since its last report. According to exchange reported data there are now Short interest is the number of shares that have been sold short but have not yet been covered or closed out. is when a trader sells shares of a company they do not own with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.Short ...

Wed Jan 28, 2026

$6.15 | +3.36%

Momentum

Stock Market Today Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer. ImmunityBio (NASDAQ:IBRX) an immunotherapy and infectious disease drug maker closed Tuesday at $6.48 up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label expansion in bladder cancer and investors are watching next steps on the planned

Mon Jan 26, 2026

$6.21 | -3.72%

Activity

Momentum

Stock Market Today Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month. ImmunityBio (NASDAQ:IBRX) an immunity-focused biotech closed Friday&rsquo.s session at $6.45 down 12.13%. The stock is still up 63.29% in the past five days and 207.14% in the past month.

Fri Jan 23, 2026

$6.45 | -12.13%

Momentum

Stock Market Today Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses. ImmunityBio (NASDAQ:IBRX) which develops immunotherapies for cancers and infectious diseases closed Wednesday at $6.92 up 6.79%. The stock moved higher as short-sellers considered what to do after the company&rsquo.s share price tripled in just three weeks this year. Trading volume

Wed Jan 21, 2026

$6.92 | +6.79%

Momentum

ImmunityBio rally causes $492M paper losses for short sellers.

Wed Jan 21, 2026

$6.92 | +6.79%

Momentum

ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission. IBRX stock jumps 17% after FDA talks outline the path to resubmit Anktiva sBLA for papillary NMIBC with additional analyses done and filing planned soon.

Wed Jan 21, 2026

$6.92 | +6.79%

Momentum

ImmunityBio (IBRX) Rockets on 12th Day Hits Fresh High. We recently published 10 Stocks Breaking Records While Wall Street Bleeds. ImmunityBio Inc. (NASDAQ:IBRX) was one of the top performers on Tuesday. ImmunityBio saw its share prices rally for a 12th consecutive day on Tuesday reaching a fresh 52-week high as investors took heart from developments in its supplemental biologics license application (BLA) for Anktiva [….]

Wed Jan 21, 2026

$6.92 | +6.79%

Momentum

Potential

Stock Market Today Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer. ImmunityBio (NASDAQ:IBRX) an immunotherapy and infectious disease drug maker closed Tuesday at $6.48 up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label expansion in bladder cancer and investors are watching next steps on the planned

Tue Jan 20, 2026

$6.48 | +17.39%

Activity

Momentum

ImmunityBio Advances FDA Path For ANKTIVA In BCG-Unresponsive Papillary Bladder Cancer. Stock Soars . (RTTNews) - ImmunityBio Inc. (IBRX) announced that it has made progress in regulatory discussions with the FDA regarding a potential resubmission of its supplemental Biologics License Application (sBLA) for ANKTIVA (nogapendekin alfa inbakicept) in patients with BCG-unresponsive

Tue Jan 20, 2026

$6.48 | +17.39%

Momentum

Discover IBRX Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of IBRX. We're here to help you make informed investment decisions today.

FIND US ON

Receive our IBRX Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

IBRX Stock trends

IBRX Stock performance

IBRX Stock analysis

IBRX investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing IBRX

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing IBRX

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

IBRX Stock Analysis & IQ Rating | ImmunityBio

IBRX Stock IQ

IBRX Target Price

IBRX Analysts Opinion

IBRX Street Sentiment

IBRX Risk Level

IBRX Performance Sentiment

Key Price Levels

Analyst Consensus

Explore our IBRX Stock insights

Receive our IBRX Daily Alerts

IBRX Street Sentiment

IBRX Risk Level

Key Price Levels

Latest Analyst Actions

Discover IBRX Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of IBRX. We're here to help you make informed investment decisions today.

Receive our IBRX Daily Alerts

IBRX Alerts